Meet Renee Calvin. She is the primary care partner for her husband Mike, who was diagnosed with Parkinson’s disease in 2011. However, two years ago Mike’s PD progressed in an unexpected way – he began seeing things that were not there and believing things that were not true. Learn more about Renee and Mike’s story.
While reviewing data from the Parkinson's Foundation Parkinson’s Outcomes Project a year ago, I noticed a participant whose quality of life went from pretty good to terrible, then back to pretty good. I wondered, “what happened here?” The answer: psychosis.
This week the FDA approved the drug Pimavanserin (Nuplazid) for the treatment of Parkinson’s disease psychosis. There has been a critical, unmet need for development of better drugs to address hallucinations and psychosis in the setting of Parkinson's disease. We have learned over many years that typical high potency neuroleptic antipsychotic drugs (e.g.
- Hallucinations are best described as deceptions or tricks played by the brain that involve the body’s senses. Hallucinations can be seen (visual), heard (auditory), felt (tactile), smelled (olfactory) or even tasted (gustatory).
- Although they appear very real to the individual, they cannot be seen, heard, felt, smelled or tasted by another person.